サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1370889

世界のサラセミア治療市場-産業規模、シェア、動向、機会、予測、2018～2028年、タイプ別、地域別、競合

Global Thalassemia Treatment Market- Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, and Others), By Region and Competition
出版日: | 発行: TechSci Research | ページ情報: 英文 189 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

世界のサラセミア治療市場-産業規模、シェア、動向、機会、予測、2018～2028年、タイプ別、地域別、競合
出版日: 2023年10月03日
発行: TechSci Research
ページ情報: 英文 189 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のサラセミア治療市場は、2024年から2028年の予測期間中に目覚ましい成長を遂げると思われます。

これは、サラセミアの有病率の増加とその治療オプションに起因しています。サラセミアは、多くの発展途上国、特に地中海地域の主要な公衆衛生問題です。高い疾病負担により、効果的なサラセミアワクチンの強い需要が生まれています。このため、サラセミアの予防や重症度の軽減を可能にするワクチンの開発に多額の投資が行われています。世界人口の約1.5%に相当する約6～10万人の重症型β-サラセミア患者、約8～9,000万人のサラセミア保因者、毎年6万人のサラセミア患者が生まれていると推定されています。

サラセミア治療市場には、輸血、鉄キレート療法、骨髄移植など様々な種類の治療が含まれます。輸血は、欠陥のある赤血球を健康な赤血球に置き換えるのに役立つため、サラセミアの最も一般的な治療法です。しかし、輸血を頻繁に行うと体内に鉄が過剰に蓄積し、臓器障害や心不全などの合併症を引き起こす可能性があります。体内の過剰な鉄を除去するために鉄キレート療法が行われ、一方、骨髄移植はサラセミアの根治的な選択肢と考えられています。

サラセミア治療市場の成長は、頻繁な輸血による治療費、鉄キレート療法、限られた競合、ジェネリック医薬品へのアクセス制限、ワクチン接種をためらう傾向の高まり、サラセミア地域での政情不安など、いくつかの課題に直面しています。ワクチンの開発には、米国食品医薬品局（FDA）や欧州医薬品庁（EMA）などの規制機関からの承認が必要です。このプロセスには長い時間と費用がかかり、承認要件も厳しいため、中小企業にとっては困難な作業となります。

市場概要
予測期間 2024～2028年
2022年の市場規模 18億9,000万米ドル
2028年の市場規模 27億1,000万米ドル
CAGR 2023～2028年 6.14%
急成長セグメント 輸血
最大市場 北米

サラセミアの有病率の増加

サラセミアの有病率の増加は、世界のサラセミア治療市場の主要促進要因の一つです。サラセミアは、地中海、中東、アジア系の集団に多く見られる遺伝子疾患です。これらの地域ではサラセミアの有病率が高いため、効果的な治療オプションに対する需要が高まっており、世界のサラセミア治療市場の成長が予想されます。

医学における技術の進歩が市場の成長を約束する

医学における技術的進歩は、世界のサラセミア治療市場を牽引する上で重要な役割を果たしています。新しく革新的な技術の開発は、サラセミアのより効果的な治療法の開発を可能にし、患者の転帰と生活の質を向上させ、世界のサラセミア治療市場を牽引しています。

遺伝子治療は、欠損または欠陥のある遺伝子を置き換えるために、機能的な遺伝子のコピーを患者の細胞に挿入するものです。FDAが承認したサラセミア遺伝子治療には、患者一人当たり280万米ドルの費用がかかります。このアプローチは、サラセミア治療において有望な結果を示しており、開発中のいくつかの遺伝子治療が著しい有効性を示しています。新たな遺伝子治療により、輸血依存性βサラセミア患者の成人および小児の90％以上が輸血自立を達成しました。

幹細胞移植は、健康な幹細胞をサラセミア患者に移植するものです。治療費の中央値は1万2,500米ドルです。この方法は重症のサラセミア患者に根治的な選択肢を提供できるが、適合するドナーが必要であり、移植に関連した合併症のリスクがあります。適合した非血縁ドナーから移植を受けた患者の2年無サラセミア生存率は71％であったのに対し、適合した血縁ドナーから移植を受けた患者では82％でした。

Cas9は、DNAの正確な改変を可能にする画期的な遺伝子編集技術です。この技術は、根本的な遺伝的欠陥を修正することにより、サラセミア患者に根治的な選択肢を提供する可能性を秘めており、世界サラセミア治療市場の成長を促進すると期待されています。

アンメット・メディカル・ニーズの増加

アンメット・メディカル・ニーズの増加は、世界のサラセミア治療市場の成長を牽引する要因の一つです。サラセミアは、ヘモグロビンの産生に影響を与え、貧血やその他の合併症を引き起こす遺伝子疾患です。重症度は様々で、重症型のサラセミア患者は定期的な輸血やその他の支持療法を必要とします。ルスパテルセプトは、定期的な輸血を必要とする成人のB型サラセミア患者における貧血治療薬です。多くの患者はいまだに頻繁な輸血を必要とし、この疾患に伴う合併症に苦しんでいます。さらに、現在の治療法は高価であり、継続的なモニタリングと管理が必要であるため、患者やその家族にとって負担となる可能性があります。サラセミアに対する新しく効果的な治療法、特に患者に根治的な選択肢を提供できる治療法に対する需要が高まっています。この需要により、遺伝子治療や遺伝子編集などの新しい治療法が開発され、多発性骨髄腫の治癒が期待されています。特に新興諸国では、サラセミアの有病率が増加の一途をたどっており、これらの治療に対する需要は拡大し、世界のサラセミア治療市場の成長を牽引すると予想されます。

調査範囲

本レポートでは、世界のサラセミア治療市場を、以下に詳述した業界動向に加えて、以下のカテゴリーに分類しています。

世界のサラセミア治療市場：タイプ別

  • 輸血
  • 鉄キレート療法
  • 血液・骨髄移植
  • その他

サラセミア治療の世界市場：地域別

  • 北米
  • 米国
  • カナダ
  • メキシコ
  • 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • アジア太平洋
  • 中国
  • インド
  • マレーシア
  • タイ
  • ベトナム
  • 南米
  • ブラジル
  • アルゼンチン
  • 中東＆アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト
  • バーレーン
  • カタール
  • クウェート
  • トルコ

競合情勢

  • 企業プロファイル：世界のサラセミア治療市場における主要企業の詳細分析

利用可能なカスタマイズ：

  • TechSci Research社は、与えられた市場データをもとに、企業固有のニーズに応じたカスタマイズを提供しています。レポートでは以下のカスタマイズが可能です。

企業情報

  • 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 COVID-19が世界のサラセミア治療薬市場に与える影響

第6章 臨床試験分析

第7章 臨床試験分析世界のサラセミア治療市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • タイプ別（輸血、鉄キレート療法、血液・骨髄移植、その他）
    • 地域別
    • 企業別（2022年）
  • 市場マップ
    • タイプ別
    • 地域別

第8章 北米のサラセミア治療市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 国別
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第9章 欧州のサラセミア治療市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 国別
  • 欧州：国別分析
    • ドイツ
    • フランス
    • 英国
    • スペイン
    • イタリア

第10章 アジア太平洋のサラセミア治療市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 国別
  • アジア太平洋：国別分析
    • 中国
    • マレーシア
    • タイ
    • ベトナム
    • インド

第11章 南米のサラセミア治療市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン

第12章 中東・アフリカのサラセミア治療市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 国別
  • 中東・アフリカ：国別分析
    • エジプト
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • バーレーン
    • カタール
    • クウェート
    • トルコ

第13章 市場力学

  • 促進要因
  • 課題

第14章 市場動向と発展

  • 製品上市
  • 合併と買収

第15章 世界のサラセミア治療市場：SWOT分析

第16章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第17章 競合情勢

  • Bluebird bio, Inc.
  • Acceleron Pharma, Inc.
  • Celgene Corporation
  • GlaxoSmithKline plc
  • Incyte Corporation
  • La Jolla Pharmaceutical Company
  • Ionis Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Lonza Group Ltd.
  • ApoPharma Inc

第18章 戦略的提言

当社について＆免責事項

目次
Product Code: 15590

Global thalassemia treatment market will witness an impressive growth during the forecast period, 2024-2028. This can be ascribed to the increasing prevalence of thalassemia and its treatment options. Thalassemia is a major public health problem in many developing countries, particularly in Mediterranean region. The high burden of disease has created a strong demand for effective thalassemia vaccines. This has led to significant investment in the development of vaccines that can prevent thalassemia or reduce its severity. It is estimated that there are around 60,000 to 100,000 babies born with severe forms of Beta-thalassemia each year globally, which is around 1.5% of the global population, around 80-90 million are carriers of thalassemia and 60000 individuals are born annually with thalassemia.

The thalassemia treatment market includes various types of therapies such as blood transfusions, iron chelation therapy, and bone marrow transplantation. Blood transfusions are the most common treatment for thalassemia, as they help to replace the defective red blood cells with healthy ones. However, frequent blood transfusions can lead to an excess buildup of iron in the body, which can cause complications such as organ damage and heart failure. Iron chelation therapy is used to remove excess iron from the body, while bone marrow transplantation is considered a curative option for thalassemia.

The growth of the Thalassemia treatment market faces several challenges, including treatment cost due to the frequent blood transfusions, Iron chelation therapy, limited competition, and limited access to generic drugs and the growing trend of vaccine hesitancy and political instability in thalassemic areas. Developing a vaccine requires approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This process can be lengthy and expensive, and the requirements for approval can be stringent, making it difficult for smaller companies to navigate the process.

Market Overview
Forecast Period2024-2028
Market Size 2022USD1.89 Billion
Market Size 2028USD2.71 Billion
CAGR 2023-20286.14%
Fastest Growing SegmentBlood Transfusion
Largest MarketNorth America

Increasing Prevalence of Thalassemia

The increasing prevalence of thalassemia is one of the key drivers of the global thalassemia treatment market. Thalassemia is a genetic disorder that is most found in populations of Mediterranean, Middle East, and Asian descent. The high prevalence of thalassemia in these regions has resulted in growing demand for effective treatment options may be anticipated in the growth of Global thalassemia treatment market.

As the global population continues to grow, the number of people with thalassemia is expected to increase. According to the World Health Organization, thalassemia is one of the most common genetic disorders worldwide, with approximately 300,000 to 500,000 children born with the disease each year. Such increasing prevalence of thalassemia is expected to drive demand for thalassemia treatment market.

Pharmaceutical companies are investing heavily in research and development for new treatments for thalassemia, including gene therapy and fetal hemoglobin induction. These treatments have the potential to provide a curative option for patients with thalassemia, which could significantly improve patient outcomes and quality of life.

Bluebird Bio is developing a gene therapy called Zynteglo (autologous CD34+ cells encoding BA-T87Q-globin gene) for the treatment of transfusion-dependent B-thalassemia. Sangamo Therapeutics is developing a gene therapy called ST-400 for the treatment of B-thalassemia. Hence, it is expected to drive global thalassemia treatment market.

Technological Advancements In Medical Science Promises The Growth Of Market

Technological advancements in medical science have played a significant role in driving the global thalassemia treatment market. The development of new and innovative technologies has enabled the development of more effective treatments for thalassemia, improving patient outcomes and quality of life drives the market of global thalassemia treatment market.

Gene therapy involves the insertion of a functional copy of a gene into a patient's cells to replace a defective or missing gene. FDA approved thalassemia gene therapy treatment costing USD 2.8M per patient. This approach has shown promising results in the treatment of thalassemia, with several gene therapies in development that have shown significant efficacy new gene treatment helped more than 90% of adult and pediatric patients with transfusion-dependent beta-thalassemia achieve transfusion independence.

Stem cell transplantation involves the transplantation of healthy stem cells into a patient with thalassemia. The median cost for treatment is USD 12500. This approach can provide a curative option for patients with severe thalassemia, but it requires a compatible donor and carries the risk of transplant-related complications. Patients who got transplants from matched unrelated donors had a 71% 2-year thalassemia-free survival rate, compared to 82% for patients who received transplants from matched related donors.

Cas9 is a revolutionary gene editing technology that enables precise modification of DNA. This technology has the potential to provide a curative option for patients with thalassemia by correcting the underlying genetic defect is expected to drive the growth of Global Thalassemia Treatment Market.

Increase in Unmet Medical Needs

The increase in unmet medical need has been one of the driving factors behind the growth of the global thalassemia treatment market. Thalassemia is a genetic disorder that affects the production of hemoglobin, leading to anemia and other complications. The severity of the disease can vary widely, and patients with severe forms of thalassemia require regular blood transfusions and other supportive care to manage their symptoms. The availability of some treatments for thalassemia, such as Luspatercept is a treatment for anemia in adults with B-thalassemia who require regular blood transfusions, there remains a significant unmet medical need in this patient population. Many patients still require frequent transfusions and suffer from the complications associated with the disease. In addition, current treatments can be expensive and require ongoing monitoring and management, which can be burdensome for patients and their families. there is a growing demand for new and more effective treatments for thalassemia, particularly those that can provide a curative option for patients. This demand has driven the development of new treatments, such as gene therapy and gene editing, which has the potential to provide a cure for thalassemia the development of new treatments, the increase in unmet medical need has created a growing market for existing treatments, such as blood transfusions and chelation therapy. As the prevalence of thalassemia continues to increase, particularly in developing countries, the demand for these treatments is expected to grow, driving the growth of the global thalassemia treatment market.

Market Segmentation

Global thalassemia treatment market can be segmented by type and region. Based on type, the global thalassemia treatment market can be divided into blood transfusions, iron chelation therapy, blood & bone marrow transplant, and others. Regionally, the thalassemia treatment market can be categorized into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

Bluebird bio, Inc., Acceleron Pharma, Inc., Celgene Corporation, GlaxoSmithKline plc, Incyte Corporation, La Jolla Pharmaceutical Company, Ionis Pharmaceuticals, Inc., Sanofi S.A., Lonza Group Ltd., and ApoPharma Inc are some of the leading players operating in the global thalassemia treatment market.

Report Scope:

In this report, Global Thalassemia Treatment Market has been segmented into following categories, in addition to the industry trends which have also been detailed below.

Global Thalassemia Treatment Market, By Type:

  • Blood Transfusions
  • Iron Chelation Therapy
  • Blood & Bone Marrow Transplant
  • Others

Global Thalassemia Treatment Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Asia Pacific
  • China
  • India
  • Malaysia
  • Thailand
  • Vietnam
  • South America
  • Brazil
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Bahrain
  • Qatar
  • Kuwait
  • Turkey

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in Global Thalassemia Treatment Market.

Available Customizations:

  • With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Impact of COVID-19 on Global Thalassemia Treatment Market

6. Clinical Trial Analysis

  • 6.1. Ongoing Clinical Trials
  • 6.2. Completed Clinical Trials
  • 6.3. Terminated Clinical Trials
  • 6.4. Breakdown of Pipeline, By Development Phase
  • 6.5. Breakdown of Pipeline, By Status
  • 6.6. Breakdown of Pipeline, By Study Type
  • 6.7. Breakdown of Pipeline, By Region
  • 6.8. Clinical Trials Heat Map

7. Global Thalassemia Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
      • 7.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 7.2.2. By Region
    • 7.2.3. By Company (2022)
  • 7.3. Market Map
    • 7.3.1. By Type
    • 7.3.2. By Region

8. North America Thalassemia Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
      • 8.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 8.2.2. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Thalassemia Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 8.3.1.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 8.3.2. Canada Thalassemia Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 8.3.2.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 8.3.3. Mexico Thalassemia Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 8.3.3.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))

9. Europe Thalassemia Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
      • 9.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 9.2.2. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. Germany Thalassemia Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 9.3.1.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 9.3.2. France Thalassemia Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 9.3.2.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 9.3.3. United Kingdom Thalassemia Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 9.3.3.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 9.3.4. Spain Thalassemia Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 9.3.4.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 9.3.5. Italy Thalassemia Treatment Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 9.3.5.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))

10. Asia-Pacific Thalassemia Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
      • 10.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 10.2.2. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Thalassemia Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 10.3.1.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 10.3.2. Malaysia Thalassemia Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 10.3.2.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 10.3.3. Thailand Thalassemia Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 10.3.3.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 10.3.4. Vietnam Thalassemia Treatment Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 10.3.4.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 10.3.5. India Thalassemia Treatment Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 10.3.5.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))

11. South America Thalassemia Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
      • 11.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 11.2.2. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Thalassemia Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 11.3.1.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 11.3.2. Argentina Thalassemia Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 11.3.2.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))

12. Middle East and Africa Thalassemia Treatment Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
      • 12.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 12.2.2. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. Egypt Thalassemia Treatment Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 12.3.1.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 12.3.2. South Africa Thalassemia Treatment Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 12.3.2.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 12.3.3. Saudi Arabia Thalassemia Treatment Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 12.3.3.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 12.3.4. UAE Thalassemia Treatment Market Outlook
      • 12.3.4.1. Market Size & Forecast
        • 12.3.4.1.1. By Value
      • 12.3.4.2. Market Share & Forecast
        • 12.3.4.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 12.3.4.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 12.3.5. Bahrain Thalassemia Treatment Market Outlook
      • 12.3.5.1. Market Size & Forecast
        • 12.3.5.1.1. By Value
      • 12.3.5.2. Market Share & Forecast
        • 12.3.5.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 12.3.5.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 12.3.6. Qatar Thalassemia Treatment Market Outlook
      • 12.3.6.1. Market Size & Forecast
        • 12.3.6.1.1. By Value
      • 12.3.6.2. Market Share & Forecast
        • 12.3.6.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 12.3.6.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 12.3.7. Kuwait Thalassemia Treatment Market Outlook
      • 12.3.7.1. Market Size & Forecast
        • 12.3.7.1.1. By Value
      • 12.3.7.2. Market Share & Forecast
        • 12.3.7.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 12.3.7.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
    • 12.3.8. Turkey Thalassemia Treatment Market Outlook
      • 12.3.8.1. Market Size & Forecast
        • 12.3.8.1.1. By Value
      • 12.3.8.2. Market Share & Forecast
        • 12.3.8.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
        • 12.3.8.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

  • 14.1. Product Launches
  • 14.2. Mergers & Acquisitions
  • 14.3. Recent Developments

15. Global Thalassemia Treatment Market: SWOT Analysis

16. Porter's Five Forces Analysis

  • 16.1. Competition in the Industry
  • 16.2. Potential of New Entrants
  • 16.3. Power of Suppliers
  • 16.4. Power of Customers
  • 16.5. Threat of Substitute Products

17. Competitive Landscape

  • 17.1. Business Overview
  • 17.2. Company Snapshot
  • 17.3. Products & Services
  • 17.4. Financials (In case of listed companies)
  • 17.5. Recent Developments
  • 17.6. SWOT Analysis
    • 17.6.1. Bluebird bio, Inc.
    • 17.6.2. Acceleron Pharma, Inc.
    • 17.6.3. Celgene Corporation
    • 17.6.4. GlaxoSmithKline plc
    • 17.6.5. Incyte Corporation
    • 17.6.6. La Jolla Pharmaceutical Company
    • 17.6.7. Ionis Pharmaceuticals, Inc.
    • 17.6.8. Sanofi S.A.
    • 17.6.9. Lonza Group Ltd.
    • 17.6.10. ApoPharma Inc

18. Strategic Recommendations

About Us & Disclaimer